Despite the initial success of androgen deprivation therapy (ADT) in treating hormone-sensitive prostate adenocarcinoma, patients inevitably develop tumors that become unresponsive to ADT known as castration-resistant prostate cancer (CRPC). CRPC represents a heterogeneous disease including multiple molecular phenotypes and clinical presentations including small cell neuroendocrine prostate cancer (NEPC) which encompasses approximately 20% of CRPC. NEPC is a poorly differentiated, highly aggressive form of prostate cancer that is usually non-responsive to the standard CRPC treatment modalities such as chemo- and radiation therapies and for which we currently have no effective treatment options.